RSTA/AGILENT Alliance VERY POSTIVE HERE
Monday August 28, 5:19 am Eastern Time
Agilent Technologies forms life sciences unit
PALO ALTO, Calif., Aug 28 (Reuters) - Test and measurement equipment maker Agilent Technologies Inc. (NYSE:A - news) said Monday it formed a new unit within its chemical analysis group to address growing demand for life sciences products.
The new Life Sciences Business Unit will focus on genomics, chemical and biochemical measurements, microfluidics, informatics and other analytical areas to the company's growing customer base in the pharmaceutical, agricultural and genomics markets, Agilent said.
The unit will be headed up by Bill Buffington as vice president and general manager reporting to Rick Kniss, head of the Chemical Analysis Group.
``By organising our R&D (research and development), marketing and sales organisations into a focused Life Sciences Business Unit, we can capitalise on opportunities in the bioscience and pharmaceutical markets with greater speed and agility,'' said Kniss.
Last months RSTA press release:
July 24, 2000
Agilent Technologies And Rosetta Inpharmatics License Rosetta Resolver™ Data Analysis System To The Harvard Center For Genomics Research
PALO ALTO, Calif., and KIRKLAND, Wash., July 24, 2000 -- Agilent Technologies Inc (NYSE: A) and Rosetta Inpharmatics Inc. today announced that the Center for Genomics Research at Harvard University has licensed the Rosetta Resolver Expression Data Analysis System for life science work. The Rosetta Resolver package is an enterprise-level bioinformatics system for gene expression research developed by Rosetta Inpharmatics and exclusively distributed by Agilent Technologies. The Rosetta Resolver System will be used by the Center to analyze data from a variety of commercial and internally developed DNA chip technologies, including Affymetrix GeneChip® arrays.
Formed a year ago, the Harvard Center for Genomics Research integrates scientific and engineering disciplines in order to develop new genomics tools and to apply them to biological problems. The Center provides access to genomics technologies to a broad range of research groups from the various schools and hospitals affiliated with Harvard.
"The demands on the Genomics Center for gene microarray expression analysis are increasing dramatically and we needed an analysis system with a suite of bioinformatics tools that is both customizable and available now," said Dr. George Busby, director of administration of the Center for Genomics Research. "Given the vast amounts of data generated by our microarray experiments, we wanted an enterprise-level tool that is capable of analyzing and storing massive quantities of data from multiple microarray platforms."
"We are pleased to have one of the world's most prestigious academic institutions licensing the Rosetta Resolver™ System," said Bill Buffington, vice president and general manager of Agilent's Bioscience Products Group. "We believe that Rosetta Inpharmatics provides the industry's most powerful bioinformatics platform, and selection of the Rosetta Resolver™ package by Harvard's Center for Genomics Research for their multi-department gene expression program serves to highlight that leadership. Agilent is pleased to be offering the Rosetta Resolver™ System as part of a rapidly expanding portfolio of products for our growing base of life sciences customers."
About Rosetta Inpharmatics
Rosetta Inpharmatics offers solutions to the emerging field of informational genomics. By combining the power of informatics and genomics, Rosetta Inpharmatics has created a proprietary platform that accelerates and enhances the drug discovery process for pharmaceutical and biotechnology companies, and improves agricultural products. Rosetta Inpharmatics' approach converts the rapidly growing amount of gene expression data, or information about a gene's activity, into organized, statistically driven, information-based results. Rosetta Inpharmatics provides a proprietary gene expression profiling platform, consisting of hardware and software products, that uses gene expression profiles to provide seamless solutions for efficient, cost-effective and powerful discovery programs. Rosetta Inpharmatics' technology builds a critical mass of coherent gene expression data collected from DNA microarrays, which are comprised of DNA fragments attached to glass slides in a grid-like formation. This platform provides comprehensive, simultaneous descriptions of a compound's effect on all relevant targets within a cell
July 24, 2000
Agilent Technologies And Rosetta Inpharmatics License Rosetta Resolver™ Data Analysis System To The Harvard Center For Genomics Research
PALO ALTO, Calif., and KIRKLAND, Wash., July 24, 2000 -- Agilent Technologies Inc (NYSE: A) and Rosetta Inpharmatics Inc. today announced that the Center for Genomics Research at Harvard University has licensed the Rosetta Resolver Expression Data Analysis System for life science work. The Rosetta Resolver package is an enterprise-level bioinformatics system for gene expression research developed by Rosetta Inpharmatics and exclusively distributed by Agilent Technologies. The Rosetta Resolver System will be used by the Center to analyze data from a variety of commercial and internally developed DNA chip technologies, including Affymetrix GeneChip® arrays.
Formed a year ago, the Harvard Center for Genomics Research integrates scientific and engineering disciplines in order to develop new genomics tools and to apply them to biological problems. The Center provides access to genomics technologies to a broad range of research groups from the various schools and hospitals affiliated with Harvard.
"The demands on the Genomics Center for gene microarray expression analysis are increasing dramatically and we needed an analysis system with a suite of bioinformatics tools that is both customizable and available now," said Dr. George Busby, director of administration of the Center for Genomics Research. "Given the vast amounts of data generated by our microarray experiments, we wanted an enterprise-level tool that is capable of analyzing and storing massive quantities of data from multiple microarray platforms."
"We are pleased to have one of the world's most prestigious academic institutions licensing the Rosetta Resolver™ System," said Bill Buffington, vice president and general manager of Agilent's Bioscience Products Group. "We believe that Rosetta Inpharmatics provides the industry's most powerful bioinformatics platform, and selection of the Rosetta Resolver™ package by Harvard's Center for Genomics Research for their multi-department gene expression program serves to highlight that leadership. Agilent is pleased to be offering the Rosetta Resolver™ System as part of a rapidly expanding portfolio of products for our growing base of life sciences customers."
About Rosetta Inpharmatics
Rosetta Inpharmatics offers solutions to the emerging field of informational genomics. By combining the power of informatics and genomics, Rosetta Inpharmatics has created a proprietary platform that accelerates and enhances the drug discovery process for pharmaceutical and biotechnology companies, and improves agricultural products. Rosetta Inpharmatics' approach converts the rapidly growing amount of gene expression data, or information about a gene's activity, into organized, statistically driven, information-based results. Rosetta Inpharmatics provides a proprietary gene expression profiling platform, consisting of hardware and software products, that uses gene expression profiles to provide seamless solutions for efficient, cost-effective and powerful discovery programs. Rosetta Inpharmatics' technology builds a critical mass of coherent gene expression data collected from DNA microarrays, which are comprised of DNA fragments attached to glass slides in a grid-like formation. This platform provides comprehensive, simultaneous descriptions of a compound's effect on all relevant targets within a cell |
